Literature DB >> 9543130

Quality of life among formerly treated childhood-onset growth hormone-deficient adults: a comparison with unaffected siblings.

D E Sandberg1, M H MacGillivray, R R Clopper, C Fung, L LeRoux, D E Alliger.   

Abstract

Several studies have investigated the quality of life (QOL) of GH-deficient (GHD) adults who, as children, had been treated with GH. Variable findings are probably related to sample heterogeneity and disparate research methodologies and designs, particularly the choice of control or comparison groups. In addition to comparing a relatively large sample to questionnaire norms, the present study is the first to compare the QOL adjustment of GHD patients to that of same sex siblings. A total of 140 former patients (76% of those eligible; mean age, 26 yr; n = 95 isolated GHD, n = 45 multiple pituitary hormone deficiencies; 117 males and 23 females) and 53 same sex siblings (84% participation), 18 yr and older, participated in the telephone questionnaire survey. The majority of interviews with GHD patients (78%) and siblings (87%) were conducted blind to the subject's clinical status. Comparisons between GHD patients and norms for standardized questionnaires indicated both better and worse functioning in several domains. In contrast, very limited differences were detected between GHD cases and same sex siblings. Isolated GHD patients were functioning better than those with multiple pituitary hormone deficiencies, but the effect sizes of these differences in most areas were relatively small. Adult height and degree of growth over the course of GH therapy were generally unrelated to QOL outcomes. Findings from the present study underscore the importance of selecting unbiased control/comparison groups in evaluating psychological outcomes among GHD adults.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9543130     DOI: 10.1210/jcem.83.4.4712

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  The impact of short stature on health-related quality of life in children with chronic kidney disease.

Authors:  Amira Al-Uzri; Matthew Matheson; Debbie S Gipson; Susan R Mendley; Stephen R Hooper; Ora Yadin; David J Rozansky; Marva Moxey-Mims; Susan L Furth; Bradley A Warady; Arlene C Gerson
Journal:  J Pediatr       Date:  2013-04-26       Impact factor: 4.406

Review 2.  Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.

Authors:  Xin He; Ariel L Barkan
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

Review 3.  Growth hormone therapy in childhood-onset growth hormone deficiency: adult anthropometric and psychological outcomes.

Authors:  D E Sandberg; M H MacGillivray
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.925

4.  Health-Related Quality of Life of Young Adults Treated with Recombinant Human Growth Hormone during Childhood.

Authors:  Grit Sommer; Micol E Gianinazzi; Rahel Kuonen; Julia Bohlius; Dagmar l'Allemand; Michael Hauschild; Primus-Eugen Mullis; Claudia E Kuehni
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

5.  Idiopathic short stature: conundrums of definition and treatment.

Authors:  Arlan L Rosenbloom
Journal:  Int J Pediatr Endocrinol       Date:  2009-03-12

Review 6.  Association of growth hormone deficiency (GHD) with anxiety and depression: experimental data and evidence from GHD children and adolescents.

Authors:  Fotini-Heleni Karachaliou; Kyriaki Karavanaki; Aristofania Simatou; Eleni Tsintzou; Nikitas S Skarakis; Christina Kanaka-Gatenbein
Journal:  Hormones (Athens)       Date:  2021-07-01       Impact factor: 2.885

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.